Drugs / GSK2485852
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01332552 | Jan → Apr 2011 | hepatitis C virus infection | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2485852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01332552 ↗ |
| Action | Inhibit | “GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed for the treatment of chronic HCV infection.” NCT01332552 ↗ |